In breast cancer mice models, olaparib could increase the antitumor efficacy of chimeric antigen receptor modified T (CAR-T) cell therapy at least partially through suppressing MDSC migration inhibiting the CXCL12-CXCR4 axis (22). This evidence concerns the gene CXCR4 and breast cancer.